Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 676

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 676
---
 with the Cayman Registrar, the filing of the Articles of the Surviving Subsidiary and the Company M&A with the Cayman Registrar and publication of notification of the Merger in the Cayman Islands Government Gazette, in each case in accordance with the Cayman Companies Act, (c) for any filings or approvals required under any applicable antitrust or competition Law, including Argentine Law No. 27,442 ( Ley de Defensa de la Competencia ), and (d) as and where the failure to obtain such consents, approvals, authorizations, designations, declarations, or waivers, or to make such filings or notifications, would not, individually or in the aggregate, prevent or materially delay the consummation of any of the Transactions or otherwise prevent the Company from performing its material obligations under this Agreement and each such Transaction Document. Section 4.6 Capitalization of the Company . (a)As of the date of this Agreement, the authorized share capital of the Company consists of $50,000.00, divided into 500,000,000 Company Shares of which 30,000,000 Company Shares, in aggregate, are issued and outstanding. Set forth on Section 4.6(a) of the Company Disclosure Letter is a true, correct and complete list of each record holder of Company Shares and the number of Company Shares held by each such holder as of the date of this Agreement, which in aggregate constitute the entire issued, outstanding and paid-up share capital of the Company as of the date of this Agreement. (b)On the Closing Date, upon the completion of the Restructuring and the MultiplAI Contribution, immediately prior to the Merger Effective Time, the authorized share capital of the Company shall consist of $50,000.00, divided into 500,000,000 Company Shares of which no more than 34,000,000 Company Shares (including Company Shares corresponding to the MultiplAI Share Consideration) shall be issued and outstanding on a fully diluted basis in addition to any Company Shares issued pursuant to the PIPE Subscription Agreements and the Backstop Agreement; provided, however, that if the MultiplAI Share Purchase Agreement has been terminated in accordance with its terms and the MultiplAI Contribution has not been consummated, no more than 30,000,000 Company Shares shall be issued and outstanding on a fully diluted basis immediately prior to the Merger Effective Time, in addition to any Company Shares issued pursuant to the PIPE Subscription Agreements and the Backstop Agreement.